One Drop Enters Global Partnership with Bayer to Leverage its A.I.

One Drop, a leader in the development of digital therapeutic solutions for diabetes and other chronic conditions, today announced a new partnership with Bayer, one of the largest pharmaceutical companies in the world.

The agreement also follows a $40 million in Series B financing, led by Bayer.

Bayer has also entered a commercial licensing agreement to use One Drop’s platform in Bayer’s global bio-digital efforts in therapeutic areas such as oncology, cardiovascular disease, and women’s health.

One Drop’s integrated platform offers an easy and effective way for people to track and manage a variety of health conditions.

With A.I.-powered behavioral recommendations, dedicated one-on-one coaching recognized by the American Diabetes Association, and thousands of app and device integrations, One Drop provides personalized health programs to drive sustainable behavior change as part of a diabetes management plan.

Through the new licensing agreement, Bayer will leverage One Drop’s data science and predictive capabilities, and harness its mobile platform to deliver innovative bio-digital solutions across a broad array of therapeutic areas.

“With today’s global digital infrastructure, there should be nothing that prevents us from delivering quality care to everyone who needs it. One Drop is leveraging this infrastructure to provide evidence-based, hyper-personalized diabetes support to millions of people each day,” said Jeff Dachis, One Drop Founder and CEO.

“As a new investor and commercial partner, Bayer is validating One Drop’s superior user experience, modular and extensible product offering, and ability to bring affordable, accessible healthcare to millions of people worldwide,” he added.

For more information about One Drop, visit at https://onedrop.today.